Arun Azad

UpFrontPSMA: a randomized phase 2 study of sequential Lu-177-PSMA-617 and docetaxel vs docetaxel in metastatic hormone-naive prostate cancer (clinical trial protocol)

Nattakorn Dhiantravan, Louise Emmett, Anthony M Joshua, David A Pattison, Roslyn J Francis, Scott Williams, Shahneen Sandhu, Ian D Davis, Ian Vela, Nitika Neha, Mathias Bressel, Declan G Murphy, Michael S Hofman, Arun A Azad

Journal article  |  2021  |  BJU International

OBJECTIVE: To assess the activity and safety of sequential lutetium-177 (177 Lu)-PSMA-617 and docetaxel vs docetaxel on a backgrou..

Plasma Cell–Free DNA Profiling of PTEN-PI3K-AKT Pathway Aberrations in Metastatic Castration-Resistant Prostate Cancer

Edmond M Kwan, Chao Dai, Heidi Fettke, Christine Hauser, Maria M Docanto, Patricia Bukczynska, Nicole Ng, Siavash Foroughi, Lisa-Jane K Graham, Kate Mahon, Winston Tan, Xiaohong Wang, Zhixin Zhao, Tiantian Zheng, Kemin Zhou, Jianjun Yu, Pan Du, Lisa G Horvath, Shidong Jia, Manish Kohli, et al.

Journal article  |  2021  |  JCO Precision Oncology

PURPOSE Tumor tissue from metastatic castration-resistant prostate cancer (mCRPC) harbors frequent copy number variations (CNVs) i..

A phase I/II study of stereotactic radiotherapy and pembrolizumab for oligometastatic renal tumours (RAPPORT): Clinical trial protocol

David Pryor, Mathias Bressel, Nathan Lawrentschuk, Ben Tran, Jennifer Mooi, Jeremy Lewin, Arun Azad, Duncan Colyer, Nitika Neha, Mark Shaw, Sarat Chander, Paul Neeson, Daniel Moon, Katharine Cuff, Simon Wood, Declan G Murphy, Shahneen Sandhu, Sherene Loi, Shankar Siva

Journal article  |  2021  |  Contemporary Clinical Trials Communications

Background: The management of oligometastatic clear cell renal cell carcinoma (ccRCC) varies widely, ranging from observation to r..

Clinical Trial Protocol for LuTectomy: A Single-arm Study of the Dosimetry, Safety, and Potential Benefit of Lu-177-PSMA-617 Prior to Prostatectomy

Nattakorn Dhiantravan, John Violet, Renu Eapen, Omar Alghazo, Mark Scalzo, Price Jackson, Simon P Keam, Catherine Mitchell, Paul J Neeson, Shahneen Sandhu, Scott G Williams, Daniel Moon, Nathan Lawrentschuk, Arun Azad, Michael S Hofman, Declan G Murphy

Journal article  |  2021  |  European Urology Focus

LuTectomy is an open-label phase 1/2 nonrandomised clinical trial evaluating the dosimetry, efficacy, and toxicity of the lutetium..

Plasma cell-free DNA profiling of PI3K/Akt pathway aberrations in two multi-institutional independent metastatic castration-resistant prostate cancer (mCRPC) cohorts.

Edmond Michael Kwan, Chao Dai, Heidi Fettke, Christine Hauser, Patricia Bukczynska, Nicole Ng, Siavash Foroughi, Lisa-Jane K Graham, Kate Lynette Mahon, Winston Tan, Amy Wang, Zhixin Zhao, Tiantian Zheng, Kemin Zhou, Jian-Jun Yu, Peter Du, Lisa Horvath, Shidong Jia, Manish Kohli, Arun Azad

Conference Proceedings  |  2021  |  Journal of Clinical Oncology

159 Background: Tumour tissue from metastatic castration-resistant prostate cancer (mCRPC) harbors frequent copy number variation..

Study of the dosimetry, safety, and potential benefit of 177Lu-PSMA-617 radionuclide therapy prior to radical prostatectomy in men with high-risk localized prostate cancer (LuTectomy study).

Omar Alghazo, Renu Eapen, Nattakorn Dhiantravan, John A Violet, Price Jackson, Mark Scalzo, Simon P Keam, Catherine Mitchell, Paul J Neeson, Shahneen Kaur Sandhu, Scott Williams, Daniel Moon, Nathan Lawrentschuk, Arun Azad, Michael S Hofman, Declan G Murphy

Conference Proceedings  |  2021  |  Journal of Clinical Oncology

TPS264 Background: High-risk localised prostate cancer (HRCaP) is treated by radical prostatectomy (RP) or radiotherapy. Despite ..

ENZA-p: A randomized phase II trial using PSMA as a therapeutic agent and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901).

Louise Emmett, Shalini Subramaniam, Alison Yan Zhang, Andrew James Martin, Sonia Yip, Megan Crumbaker, Nisha Rana, Kate Ford, Ailsa Langford, Roslyn J Francis, Michael S Hofman, Anthony M Joshua, Shahneen Kaur Sandhu, Arun Azad, Craig Gedye, Margaret Mary McJannett, Martin R Stockler, Ian D Davis

Conference Proceedings  |  2021  |  Journal of Clinical Oncology

TPS177 Background: 177Lu‐PSMA‐617 (LuPSMA) is a novel radionuclide with promising activity and tolerability in metastatic, castra..

Stereotactic radiotherapy and pembrolizumab for oligometastatic renal tumors: The RAPPORT trial.

Shankar Siva, Mathias Bressel, Simon Wood, Mark Shaw, Sherene Loi, Shahneen Kaur Sandhu, Ben Tran, Arun Azad, Jeremy Howard Lewin, Katharine Cuff, Nitika Neha, Duncan Colyer, Paul J Neeson, Howard Liu, Sarat Chander, Daniel Moon, Jeremy Goad, Declan G Murphy, Nathan Lawrentschuk, David Pryor

Conference Proceedings  |  2021  |  Journal of Clinical Oncology

277 Background: Pembrolizumab monotherapy, whilst not standard of care, has demonstrated efficacy in clear cell renal cell carcin..

ICEPAC: A phase II multicenter study of avelumab combined with stereotactic ablative body radiotherapy (SABR) in metastatic castration-resistant prostate cancer (mCRPC)

Arun Azad, Lavinia Anne Spain, Angelyn Anton, Chun Loo Gan, Linda Garrett, Deborah Chang, Caitlin Bennett, Gargi Kothari, Mark Shaw, Phillip Parente, Carmel Jo Pezaro, Ben Tran, Shankar Siva, Edmond Michael Kwan

Conference Proceedings  |  2021  |  Journal of Clinical Oncology

86 Background: Studies investigating immune checkpoint inhibitors (ICI) in mCRPC have produced modest results. Radiation therapy ..

Final results of a phase I/II prospective dose escalation trial evaluating safety and efficacy of combination 177Lu PSMA 617 and NOX66 in men with end-stage metastatic castration-resistant prostate cancer (LuPIN trial)

Sarennya Pathmanandavel, Megan Crumbaker, Andrew On Wah Yam, Christopher Rofe, Bao Ho, Wai Ling Chan, Shikha Sharma, Adam James Hickey, Kamonwan Kongrak, Lalith Ratnayake, Edmond Michael Kwan, Arun Azad, Peter Eu, Andrew Nguyen, Anthony M Joshua, Louise Emmett

Conference Proceedings  |  2021  |  Journal of Clinical Oncology

103 Background: 177LuPSMA – 617 is a promising therapy for metastatic castrate-resistant prostate cancer (mCRPC). However, treatm..